A light test may spot a gene change during brain surgery
Original title: Intraoperative fluorescence spectroscopy for IDH classification in glioma: a feasibility study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was an early test of a tool in a few patients, and it is not a treatment.
The short version
Doctors tried a light probe to spot a key gene change in tumor tissue during surgery.
What was studied. Twenty-seven patients had brain tumor surgery. Doctors touched a light probe to tissue samples, then taught a computer program to read the light patterns.
What they found. The team recorded over 8000 light readings. The program spotted a gene change called IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary with 87% accuracy. It could not reliably spot a second marker, called MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary.
What this means, and what it doesn't
What it could mean: Gene results usually come back days after surgery. A tool like this might give an answer while surgery is happening. That could help a surgeon plan on the spot. This was only a first test of the idea.
What it doesn't mean: This does not mean the test is ready for you or your hospital. It was an early first test in a small group of people. The tool does not treat a tumor, and it is not a cure. The team says bigger studies are needed first.
Source: PubMed, October 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.